Differences in Posttransplant Hepatocellular Carcinoma Recurrence by Etiology of Liver Disease

Nadim Mahmud, Abraham Shaked, Kim M. Olthoff, David S. Goldberg – 25 October 2018 – The 5‐year incidence of posttransplant hepatocellular carcinoma (HCC) recurrence is 8%‐20%. Several studies have evaluated pretransplant risk factors for HCC recurrence, but nearly all data have treated HCC as a homogeneous condition across all etiologies of liver disease despite differences in tumor biology and baseline incidence of HCC.

Primary Stent Placement for Hepatic Artery Stenosis After Liver Transplantation: Improving Primary Patency and Reintervention Rates

Ammar Sarwar, Christine Chen, Khalid Khwaja, Raza Malik, Kristin E. Raven, Jeffrey L. Weinstein, Amy Evenson, Salomao Faintuch, Robert Fisher, Michael P. Curry, Muneeb Ahmed – 25 October 2018 – Recent studies have reported high rates of reintervention after primary stenting for hepatic artery stenosis (HAS) due to the loss of primary patency. The aims of this study were to evaluate the outcomes of primary stenting after HAS in a large cohort with longterm follow‐up.

Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection

Shi Liu, Bin Zhou, Juan D. Valdes, Jian Sun, Haitao Guo – 25 October 2018 – Chronic hepatitis B infection is one of the major etiological causes of liver failure, cirrhosis, and hepatocellular carcinoma (HCC) worldwide. This condition cannot be completely cured by currently available drugs due to the persistent existence of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA), the bona fide transcription template for HBV RNAs, in infected hepatocytes.

Development of Clinical Criteria for Functional Assessment to Predict Primary Nonfunction of High‐Risk Livers Using Normothermic Machine Perfusion

Hynek Mergental, Barnaby T. F. Stephenson, Richard W. Laing, Amanda J. Kirkham, Desley A. H. Neil, Lorraine L. Wallace, Yuri L. Boteon, Jeannette Widmer, Ricky H. Bhogal, M. Thamara P. R. Perera, Amanda Smith, Gary M. Reynolds, Christina Yap, Stefan G. Hübscher, Darius F. Mirza, Simon C. Afford – 25 October 2018 – Increased use of high‐risk allografts is critical to meet the demand for liver transplantation. We aimed to identify criteria predicting viability of organs, currently declined for clinical transplantation, using functional assessment during normothermic machine perfusion (NMP).

Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection

Shi Liu, Bin Zhou, Juan D. Valdes, Jian Sun, Haitao Guo – 25 October 2018 – Chronic hepatitis B infection is one of the major etiological causes of liver failure, cirrhosis, and hepatocellular carcinoma (HCC) worldwide. This condition cannot be completely cured by currently available drugs due to the persistent existence of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA), the bona fide transcription template for HBV RNAs, in infected hepatocytes.

LiverLearning®: 2018 Webinar: HBV - Update on the Guidelines and Controversies in Management

This webinar focuses on reviewing the highlights of the revised AASLD Clinical Practice Guidelines for HBV infection in the first talk.  The second presentation addresses a key area of controversy, namely the role of antiviral therapy in patients during the immunotolerant phase of chronic HBV infection.Naga P. Chalasani (Moderator) Naga P. Chalasani, MD, FAASLD currently serves as David W. Crabb Professor of Medicine and Interim Chair of the Department of Medicine at Indiana University School of Medicine.

Subscribe to